Laurion Capital Management LP purchased a new stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 38,966 shares of the company’s stock, valued at approximately $1,851,000.

Several other hedge funds have also recently made changes to their positions in AERI. Neuberger Berman Group LLC boosted its holdings in Aerie Pharmaceuticals by 10.1% in the third quarter. Neuberger Berman Group LLC now owns 375,800 shares of the company’s stock valued at $23,130,000 after purchasing an additional 34,500 shares during the last quarter. Teachers Advisors LLC boosted its holdings in Aerie Pharmaceuticals by 1.1% in the third quarter. Teachers Advisors LLC now owns 70,937 shares of the company’s stock valued at $4,366,000 after purchasing an additional 772 shares during the last quarter. Bank of Montreal Can boosted its holdings in Aerie Pharmaceuticals by 40.2% in the fourth quarter. Bank of Montreal Can now owns 1,060 shares of the company’s stock valued at $38,000 after purchasing an additional 304 shares during the last quarter. Suffolk Capital Management LLC lifted its holdings in Aerie Pharmaceuticals by 10.9% during the 4th quarter. Suffolk Capital Management LLC now owns 230,149 shares of the company’s stock worth $8,308,000 after buying an additional 22,679 shares during the last quarter. Finally, JGP Global Gestao de Recursos Ltda. bought a new position in Aerie Pharmaceuticals during the 4th quarter worth approximately $279,000.

NASDAQ:AERI opened at $39.15 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.27 and a current ratio of 3.47. Aerie Pharmaceuticals Inc has a 52 week low of $32.18 and a 52 week high of $74.75. The company has a market cap of $1.79 billion, a price-to-earnings ratio of -8.42 and a beta of 0.82.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its earnings results on Tuesday, May 7th. The company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.13. The company had revenue of $10.85 million for the quarter, compared to the consensus estimate of $12.66 million. Aerie Pharmaceuticals had a negative return on equity of 93.96% and a negative net margin of 684.56%. On average, research analysts forecast that Aerie Pharmaceuticals Inc will post -2.6 earnings per share for the current fiscal year.

A number of research analysts have commented on the company. Zacks Investment Research downgraded Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, March 25th. Mizuho reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a report on Friday, February 8th. ValuEngine downgraded Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, February 5th. Canaccord Genuity set a $65.00 target price on Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, March 19th. Finally, Cantor Fitzgerald set a $85.00 target price on Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, February 26th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company. Aerie Pharmaceuticals has an average rating of “Buy” and an average target price of $75.42.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/laurion-capital-management-lp-buys-shares-of-38966-aerie-pharmaceuticals-inc-aeri/3017670.html.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Featured Story: Debt-To-Equity Ratio

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.